Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2016 Nov 15;316(19):2041-2043.
doi: 10.1001/jama.2016.13614.

Temporal Changes in the Association Between Modifiable Risk Factors and Coronary Heart Disease Incidence

Ann Marie Navar  1 , Eric D Peterson  1 , Daniel Wojdyla  1 , Robert J Sanchez  2 , Allan D Sniderman  3 , Ralph B D'Agostino Sr  4 , Michael J Pencina  1
Affiliations
Comment

Temporal Changes in the Association Between Modifiable Risk Factors and Coronary Heart Disease Incidence

Ann Marie Navar et al. JAMA. .

Erratum in

  • Label Error in Figure.
    [No authors listed] [No authors listed] JAMA. 2016 Dec 13;316(22):2433. doi: 10.1001/jama.2016.18247. JAMA. 2016. PMID: 27959981 No abstract available.
No abstract available

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest Disclosures

All authors will complete the ICMJE uniform disclosure form at www.icmje.org/coi_disclosure.pdf.

AM Navar: Dr. Navar reports research funding from Sanofi and Regeneron and consulting from Sanofi.

ED Peterson: Dr. Peterson grant support from American College of Cardiology, American Heart Association, Janssen; and consulting from Bayer, Boehringer Ingelheim, Merck, Valeant, Sanofi, Astra Zeneca, Janssen, Regeneron, Genentech.

D Wojdyla: Dr. Wojdyla has no relevant disclosures to report.

R Sanchez: Dr. Sanchez reports stockholding with Regeneron.

A Sniderman: Dr. Sniderman reports no relevant disclosures.

RB D’Agostino: Dr. D’Agostino reports no relevant disclosures.

MJ Pencina: Dr. Pencina reports funding from Regeneron and Sanofi to DCRI.

Figures

Figure
Figure. PAF of CHD
Displayed is the PAF of CHD for treatment-adjusted SBP ≥140, diabetes, smoking, and treatment-adjusted total:HDL-C ≥4.0 in the early and later eras. Abbreviations: CHD, coronary heart disease; PAF, population attributable fraction; SBP, systolic blood pressure; total:HDL-C, total-to-high-density lipoprotein cholesterol ratio
See this image and copyright information in PMC

Comment on

References

    1. Moser M. From JNC 1 to JNC 7—what have we learned? Prog Cardiovasc Dis. 2006;48(5):303–315. - PubMed
    1. Talwalkar PG, Sreenivas CG, Gulati A, Baxi H. Journey in guidelines for lipid management: from adult treatment panel (ATP)-I to ATP-III and what to expect in ATP-IV. Indian J Endocrinol Metab. 2013;17(4):628–635. - PMC - PubMed
    1. Giffen CA, Carroll LE, Adams JT, Brennan SP, Coady SA, Wagner EL. Providing contemporary access to the historical biospecimen collections: development of the NHLBI Biologic Specimen and Data Repository Information Coordinating Center (BioLINCC) Biopreserv Biobank. 2015;13(4):271–279. - PMC - PubMed
    1. Laaksonen MA, Knekt P, Härkänen T, Virtala E, Oja H. Estimation of the population attributable fraction for mortality in a cohort study using a piecewise constant hazards model. Am J Epidemiol. 2010;171(7):837–847. - PubMed
    1. Levy D, DeStefano AL, Larson MG, et al. Evidence for a gene influencing blood pressure on chromosome 17. Genome scan linkage results for longitudinal blood pressure phenotypes in subjects from the Framingham Heart Study. Hypertension. 2000;36(4):477–483. - PubMed